US · TPVG · ASSET MANAGEMENT
TriplePoint Venture Growth BDC Corp. (TPVG) intrinsic value and stock valuation
$3.42as of 2026-11-21 · Mkt cap 211.11M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
TriplePoint Venture Growth BDC Corp. DCF and intrinsic value
InvestorsCraft values TPVG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TPVG’s statements →
TriplePoint Venture Growth BDC Corp. Graham Number
Graham Number: $15.54d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $97.2M | $71.2M | $5.97M | $13.4M | $100.7M |
| Operating income | $75.7M | $32.1M | -$-39.82M | -$-20.07M | $76.6M |
| Net income | $49.2M | $32.1M | -$-39.82M | -$-20.07M | $76.6M |
| EPSd | $1.22M | $819.7K | -$-1.12M | -$-613.95K | $2.47M |
| Operating cash flow | -$-57.03M | $152.9M | $49.2M | -$-100.89M | -$-144.68M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-57.03M | $152.9M | $49.2M | -$-100.89M | -$-144.68M |
| Total assets | $839.7M | $763M | $978.8M | $1.01B | $927.7M |
| Total debt | $469.1M | $398.8M | $607.9M | $567M | $467.5M |
| Net debt | $448.7M | $352.9M | $454.6M | $515.5M | $416.2M |
| Total equity | $353.6M | $345.7M | $346.3M | $419.9M | $434.5M |
| Cash and short-term investments | $20.4M | $45.9M | $153.3M | $51.5M | $51.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $97.2M | $71.2M | $5.97M | $13.4M | $100.7M |
| Cost of revenue | $16M | $25.7M | $33M | $22.9M | $13.4M |
| Gross profit | $81.2M | $45.5M | -$-27.07M | -$-9.51M | $87.4M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $6.12M | $8.69M | $9M | $6.7M | $6.13M |
| Other expenses | -$-660K | $4.79M | $3.76M | $3.86M | $4.66M |
| Operating expenses | $5.45M | $13.5M | $12.8M | $10.6M | $10.8M |
| Cost and expenses | $21.5M | $39.1M | $45.8M | $33.5M | $24.2M |
| Interest income | $88.3M | $106.4M | $133.3M | $116.6M | $82.8M |
| Interest expense | $26.5M | $25.7M | $33M | $22.9M | $13.4M |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Ebitda | $75.7M | $32.1M | -$-39.82M | -$-20.07M | $76.6M |
| Operating income | $75.7M | $32.1M | -$-39.82M | -$-20.07M | $76.6M |
| Total other income/expenses, net | -$-26.52M | $0.00 | $0.00 | $0.00 | $0.00 |
| Income before tax | $49.2M | $32.1M | -$-39.82M | -$-20.07M | $76.6M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $49.2M | $32.1M | -$-39.82M | -$-20.07M | $76.6M |
| Weighted average shares outstanding | $40.3M | $39.1M | $35.7M | $32.7M | $30.9M |
| Weighted average diluted shares outstanding | $40.3M | $39.1M | $35.7M | $32.7M | $30.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $20.4M | $45.9M | $153.3M | $51.5M | $51.3M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $20.4M | $45.9M | $155.7M | $53.4M | $52.3M |
| Property, plant and equipment, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $783.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $819.3M | $717.1M | $823.1M | $961.2M | $875.4M |
| Total assets | $839.7M | $763M | $978.8M | $1.01B | $927.7M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Short-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term debt | $469.1M | $398.8M | $607.9M | $567M | $467.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $486M | $417.4M | $632.5M | $594.6M | $493.2M |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $486M | $417.4M | $632.5M | $594.6M | $493.2M |
| Common stock | $410K | $400K | $380K | $350K | $310K |
| Retained earnings | -$-161.18M | -$-168.43M | -$-147M | -$-50.98M | $20M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $353.6M | $345.7M | $346.3M | $419.9M | $434.5M |
| Total investments | $783.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $469.1M | $398.8M | $607.9M | $567M | $467.5M |
| Net debt | $448.7M | $352.9M | $454.6M | $515.5M | $416.2M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $49.2M | $32.1M | -$-39.82M | -$-20.07M | $76.6M |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | -$-8.38M | -$-4.6M |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-1.51M | -$-7.87M | -$-3.5M | $1.08M | $7.69M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $290K | -$-2.29M | $640K |
| Net cash provided by operating activities | -$-57.03M | $152.9M | $49.2M | -$-100.89M | -$-144.68M |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $0.00 | $0.00 | $56.9M | -$-421M | -$-417.37M |
| Common stock issued | $0.00 | $19.4M | $21.1M | $55.1M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-41.27M | -$-52.09M | -$-54.92M | -$-49.59M | -$-45.59M |
| Net cash used for financing activities | $25.7M | -$-245.78M | $6.17M | $101M | $159.2M |
| Net change in cash | -$-31.36M | -$-92.86M | $112.3M | $110K | $14.5M |
| Cash at end of period | $47.4M | $78.7M | $171.6M | $59.3M | $59.2M |
| Operating cash flow | -$-57.03M | $152.9M | $49.2M | -$-100.89M | -$-144.68M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-57.03M | $152.9M | $49.2M | -$-100.89M | -$-144.68M |
Line items
Line items
Line items
About TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.
- CEO
- James Peter Labe
- Employees
- 0
- Beta
- 1.34
Explore
Frequently asked questions
What is the intrinsic value of TriplePoint Venture Growth BDC Corp. (TPVG)?
InvestorsCraft does not currently publish an intrinsic value for TPVG. How the IC value is calculated.
Is TPVG undervalued?
InvestorsCraft does not publish an undervaluation signal for TPVG at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.